Isogenica collaborates with J&JPRD
Earlier in 2008, J&JPRD has got license to Isogenica’s CIS display technology, as successor in business to Centocor Research & Development, for application with the J&JPRD’s Centyrin scaffold
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.